INVOKANA ® (canagliflozin) Demonstrated Significant Renal Protective Benefits in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news

Related Links:

Conclusions: CD146 is associated with kidney injury and could be a good marker to predict renal outcomes in patients with early stages of DN.Cell Physiol Biochem 2018;48:63 –74
Source: Cellular Physiology and Biochemistry - Category: Cytology Source Type: research
Publication date: March 2018Source: Advances in Chronic Kidney Disease, Volume 25, Issue 2Author(s): Vikram Patney, Kunal Chaudhary, Adam Whaley-ConnellThe global incidence and prevalence of diabetes continues to expand due primarily to the influences of obesity and the contribution of obesity to the progression of type 2 diabetes mellitus. The rising prevalence of type 2 diabetes has driven an increase in rates of CKD in the past 3 decades in the United States. In turn, so have the rates for complications related to type 2 diabetes including CKD, eg, diabetic kidney disease (DKD). Although incident rates for DKD have stab...
Source: Advances in Chronic Kidney Disease - Category: Urology & Nephrology Source Type: research
Publication date: July 2018Source: The Lancet Diabetes &Endocrinology, Volume 6, Issue 7Author(s): Srinivasan Beddhu, Tom Greene, Robert Boucher, William C Cushman, Guo Wei, Gregory Stoddard, Joachim H Ix, Michel Chonchol, Holly Kramer, Alfred K Cheung, Paul L Kimmel, Paul K Whelton, Glenn M ChertowSummaryBackgroundGuidelines, including the 2017 American College of Cardiology and American Heart Association blood pressure guideline, recommend tighter control of systolic blood pressure in people with type 2 diabetes. However, it is unclear whether intensive lowering of systolic blood pressure increases the incidence of c...
Source: The Lancet Diabetes and Endocrinology - Category: Endocrinology Source Type: research
Publication date: Available online 20 June 2018Source: Canadian Journal of DiabetesAuthor(s): Adame Perez SI, Senior PA, Field CJ, Jindal K, Mager DRAbstractBackgroundFrailty can cause an increased vulnerability to adverse health outcomes such as falls, fractures, depression and reduced health related quality of life (HRQoL). This cross sectional study compared differences in body composition, HRQoL, mental health, cognitive and vitamin D (VitD) status and health care utilization between frail and non-frail adults with Diabetes Mellitus (DM Type 1 and Type 2) with chronic kidney disease (CKD stages 1-5).Methods and Partici...
Source: Canadian Journal of Diabetes - Category: Endocrinology Source Type: research
Publication date: April 2018Source: Cor et Vasa, Volume 60, Issue 2Author(s): P. LanzerAbstractMedia sclerosis Mönckeberg (MSM) is associated with progressive calcifications of the arterial wall media leaving the intima intact. MSM is frequently associated with type 2 diabetes mellitus and chronic kidney disease. In some cases, however, no risk factors are present suggesting presence of a primary dystopic calcification disorder. Here we propose diagnostic criteria and advocate dedicated research into this as yet poorly defined vascular disorder.
Source: Cor et Vasa - Category: Cardiology Source Type: research
ConclusionIn a large US-based outpatient registry, we found that a quarter of adults with T2D had a diagnosis of HF, which was predominantly HFpEF. Although certain T2D medication use in patients with HF appeared consistent with evidence (less use of thiazolidinediones), others appeared contrary to evidence (less use of metformin and SGLT2 inhibitors).
Source: American Heart Journal - Category: Cardiology Source Type: research
ConclusionsHarmony Outcomes will assess the CV safety of albiglutide in patients with T2DM and CV disease. Trials of other agents in the glucagon-like peptide-1 receptor agonist class have shown CV benefit for only some of these medications, possibly due to differences in trial design or instead due to differences in drug structure or metabolism. Harmony Outcomes will provide information critical to our understanding of this heterogenous class of glucose-lowering agents.
Source: American Heart Journal - Category: Cardiology Source Type: research
Publication date: Available online 5 June 2018Source: Seminars in Cell &Developmental BiologyAuthor(s): Robert L. ChevalierAbstractThere is a global epidemic of chronic kidney disease (CKD) characterized by a progressive loss of nephrons, ascribed in large part to a rising incidence of hypertension, metabolic syndrome, and type 2 diabetes mellitus. There is a ten-fold variation in nephron number at birth in the general population, and a 50% overall decrease in nephron number in the last decades of life. The vicious cycle of nephron loss stimulating hypertrophy by remaining nephrons and resulting in glomerulosclerosis h...
Source: Seminars in Cell and Developmental Biology - Category: Cytology Source Type: research
Publication date: Available online 31 January 2018Source: Journal of Microbiology, Immunology and InfectionAuthor(s): Ing-Kit Lee, Ching-Jung Hsieh, Chien-Te Lee, Jien-Wei LiuAbstractBackground/purposeThe impact of type 2 diabetes mellitus (DM2) on clinical severity of dengue has not been fully understood. We aimed to assess risk factors for dengue hemorrhagic fever (DHF)/dengue shock syndrome (DSS) and severe dengue (SD) (defined based on the World Health Organization 1997 and 2009 dengue classifications), and additionally identify, among DM2 patients, who are at risk for developing DHF/DSS and severe dengue.MethodsA retr...
Source: Journal of Microbiology, Immunology and Infection - Category: Microbiology Source Type: research
ConclusionsHarmony Outcomes will assess the CV safety of albiglutide in patients with T2DM and CV disease. Trials of other agents in the glucagon-like peptide-1 receptor agonist class have shown CV benefit for only some of these medications, possibly due to differences in trial design or instead due to differences in drug structure or metabolism. Harmony Outcomes will provide information critical to our understanding of this heterogenous class of glucose-lowering agents.
Source: American Heart Journal - Category: Cardiology Source Type: research
More News: Canagliflozin | Chronic Kidney Disease | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Invokana | Pharmaceuticals | Urology & Nephrology